These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 21772049)

  • 1. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.
    Kalac M; Scotto L; Marchi E; Amengual J; Seshan VE; Bhagat G; Ulahannan N; Leshchenko VV; Temkin AM; Parekh S; Tycko B; O'Connor OA
    Blood; 2011 Nov; 118(20):5506-16. PubMed ID: 21772049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
    Luszczek W; Cheriyath V; Mekhail TM; Borden EC
    Mol Cancer Ther; 2010 Aug; 9(8):2309-21. PubMed ID: 20682643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.
    Pera B; Tang T; Marullo R; Yang SN; Ahn H; Patel J; Elstrom R; Ruan J; Furman R; Leonard J; Cerchietti L; Martin P
    Clin Epigenetics; 2016; 8():79. PubMed ID: 27453763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
    Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
    Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
    Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
    Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy.
    Valdez BC; Tsimberidou AM; Yuan B; Nieto Y; Baysal MA; Chakraborty A; Andersen CR; Andersson BS
    Oncotarget; 2024 Jun; 15():361-373. PubMed ID: 38829622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy.
    Gupta M; Han JJ; Stenson M; Wellik L; Witzig TE
    Leukemia; 2012 Jun; 26(6):1356-64. PubMed ID: 22116549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.
    Mossman D; Kim KT; Scott RJ
    BMC Cancer; 2010 Jul; 10():366. PubMed ID: 20618997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia.
    Gopalakrishnapillai A; Kolb EA; McCahan SM; Barwe SP
    Leuk Res; 2017 Jul; 58():91-97. PubMed ID: 28505595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.
    Turner TB; Meza-Perez S; LondoƱo A; Katre A; Peabody JE; Smith HJ; Forero A; Norian LA; Straughn JM; Buchsbaum DJ; Randall TD; Arend RC
    Oncotarget; 2017 Jul; 8(27):44159-44170. PubMed ID: 28498806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer.
    Chan D; Zheng Y; Tyner JW; Chng WJ; Chien WW; Gery S; Leong G; Braunstein GD; Koeffler HP
    J Cancer Res Clin Oncol; 2013 Sep; 139(9):1507-14. PubMed ID: 23824064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
    Dasmahapatra G; Lembersky D; Kramer L; Fisher RI; Friedberg J; Dent P; Grant S
    Blood; 2010 Jun; 115(22):4478-87. PubMed ID: 20233973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
    Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
    J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells.
    Shaker S; Bernstein M; Momparler LF; Momparler RL
    Leuk Res; 2003 May; 27(5):437-44. PubMed ID: 12620295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
    Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
    Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transformation-dependent silencing of tumor-selective apoptosis-inducing TRAIL by DNA hypermethylation is antagonized by decitabine.
    Lund P; Kotova I; Kedinger V; Khanwalkar H; Voltz E; Hahn WC; Gronemeyer H
    Mol Cancer Ther; 2011 Sep; 10(9):1611-23. PubMed ID: 21697397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
    Steele N; Finn P; Brown R; Plumb JA
    Br J Cancer; 2009 Mar; 100(5):758-63. PubMed ID: 19259094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.
    Shieh JM; Tang YA; Hu FH; Huang WJ; Wang YJ; Jen J; Liao SY; Lu YH; Yeh YL; Wang TW; Lin P; Wang YC
    Int J Cancer; 2017 May; 140(10):2375-2386. PubMed ID: 28233309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells.
    Chan DW; Lee JM; Chan PC; Ng IO
    Int J Cancer; 2008 Sep; 123(5):1043-52. PubMed ID: 18553387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.